Favourable prognosis of trigeminal neuralgia when enrolled in a multidisciplinary management program - a two-year prospective real-life study

Table 6 Drugs used for trigeminal neuralgia at initial and follow-up assessments

	Initial assessment (n = 103) *	Dose Range (initial)	3 months assessment (n = 60)	6 months assessment (n = 71)	12 months assessment (n = 60)	Two-year assessment (n = 103)	Dose range (two-year)	P-value^#
	N (%) Cl	mg	N (%) Cl	N (%) Cl	N (%) Cl	N (%) Cl	mg
Carbamazepine	29 (28) 19–37	100–1600	22 (36) 24–47	22 (31) 21–43	15 (25) 14–37	20 (19) 12–28	200–1400	0.13
Oxcarbazepine	20 (19) 12–28	300–2400	20 (33) 22–46	18 (25) 16–37	18 (30) 19–43	30 (29) 21–39	300–2700	0.076
Gabapentin	29 (28) 20–37	600–4500	14 (23) 12–33%	17 (24) 14–36	12 (20) 10–32	24 (23) 15–32	600–3600	0.33
Pregabalin	8 (8) 3–13	150–600	7 (12) 3–19	2 (3) 0–9	6 (10) 4–21%	7 (7) 3–14	150–600	1.00
Baclofen	4 (4) 0–10	15–70	–	–	–	1 (1) 0–5	40	N/A
Valproate	4 (4) 0–10	500–1200	1 (2) 0–5	1 (1) 0–4	1 (2) 0–5	–	–	N/A
Tricyclic antidepressants	3 (3) 0–8	100–200	1 (2) 0–5	2 (2) 0–6	2 (3) 1–9	4 (4) 0–10	40–100	1.00
Lamotrigine	3 (3) 0–8	250–800	4 (6) 3–13	4 (6) 0–14	3 (5) 0–14	7 (7) 2–14	125–700	0.22
Phenytoin	1 (1) 0–5	50	–	–	–	–	–	N/A
Morphine-like drugs	2 (2) 0–7	200	–	–	–	2 (2) 0–7	200	N/A
Paracetamol	4 (4) 0–10	1000–4000	1 (2) 0–5	–	1 (2) 0–5	3 (3) 0–8	1000–4000	1.00
NSAID	2 (2) 0–7	400–1200	2 (3) 1–9	–	1 (2) 0–5	1 (1) 0–5	Md	N/A
Verapamil	1 (1) 0–7	480	–	–	1 (2) 0–5	–	–	N/A
Eslicarbazepine	–	–	–	–	–	1 (1) 0–7	800	N/A
Levetiracetam	–	–	–	–	–	1 (1) 0–7	1500	N/A

^aFishers exact test. *Represents the drugs that patients reported at their initial visit at DHC, i.e. the drugs they were using at the time of referral. ^#Mc Nemars test based on data from initial vs. two-year assessment. CL = 95% confidence limits. N/A = not applicable, Md = missing data

ISSN: 1129-2377